JULIANA FOLLONI FERNANDES
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina
33 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 33
conferenceObject NON-MYELOABLATIVE HAPLOIDENTICAL BMT WITH PTCY FOR CHILDREN AND ADULTS WITH SICKLE CELL DISEASES: THE BRAZILIAN EXPERIENCE(2023) BONFIM, Carmem; SIMOES, Belinda; GOUVEIA, Roseane V.; SILVA, Roberto Luiz; LEITE, Lauro Augusto C.; FERNANDES, Juliana Folloni; GARCIA, Julia Lopes; ZECCHIN, Victor Gottardello; LEE, Maria Lucia; KUWAHARA, Cilmara; GOMES, Alessandra Araujo; RODRIGUES, Celso Arrais; NICHELE, Samantha; LOTH, Gisele; GINANI, Valeria Cortze; FELICIANO, Joao Vitor; LIMA, Alberto Cardoso Martins; DARRIGO JR., Luiz Guilherme; FUENTE, Josu De La; KASSIM, Adetola; SEBER, AdrianaconferenceObject Hospital Length of Stay and Impact of Readmission in the First 100 Days of Allogeneic Stem Cell Transplantation: Comparison among Alternative Donor in Pediatric and Adult Population(2018) KERBAUY, Mariana Nassif; KERBAUY, Lucila Nassif; ESTEVES, Iracema; ROCHA, Juliana DallAgnol; STANZIONE, Renata Leati; RODRIGUES, Morgani; FERNANDES, Juliana Folloni; KUTNER, Jose Mauro; SOBRINHO, Jairo J. N.; MANTOVANI, Luiz Fernando Alves Lima; KERBAUY, Fabio R.; RIBEIRO, Andreza Feitosa; HAMERSCHLAK, NelsonconferenceObject The Brazilian Experience with Haploidentical Hematopoietic Cell Transplants (Haplo-HCT) with Post-Transplant Cyclophosphamide (PTCy) in Pediatric Patients with Hematological Malignancies(2020) BONFIM, Carmem; ARCURI, Leonardo J.; COLTURATO, Vergilio; ZECCHIN, Victor G.; KUWAHARA, Cilmara C.; RIBEIRO, Lisandro L.; GOUVEIA, Roseane; FERNANDES, Juliana F.; TAVARES, Rita; DAUDT, Liane E.; DARRIGO JR., Luiz G.; SOUZA, Mair P. de; ROCHA, Vanderson; VILLELA, Neysimelia C.; MARIANO, Livia C. B.; GINANI, Valeria C.; LOTH, Gisele; GOMES, Alessandra A.; ZANETTE, Antonella; HAMERSCHLAK, Nelson; FLOWERS, Mary E.- Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials(2023) LIN, Chenyu; SCHWARZBACH, Aurelie; SANZ, Jaime; MONTESINOS, Pau; STIFF, Patrick; PARIKHA, Suhag; BRUNSTEIN, Claudio; CUTLER, Corey; LINDEMANS, Caroline A.; HANNA, Rabi; KOH, Liang Piu; JAGASIA, Madan H.; VALCARCEL, David; MAZIARZ, Richard T.; KEATING, Amy K.; HWANG, William Y. K.; REZVANI, Andrew R.; KARRAS, Nicole A.; FERNANDES, Juliana F.; ROCHA, Vanderson; BADELL, Isabel; RAM, Ron; SCHILLER, Gary J.; VOLODIN, Leonid; WALTERS, Mark C.; HAMERSCHLAK, Nelson; CILLONI, Daniela; FRANKFURT, Olga; MCGUIRK, Joseph P.; KURTZBERG, Joanne; SANZ, Guillermo; SIMANTOV, Ronit; HORWITZ, Mitchell E.Omidubicel is an umbilical cord blood (UCB)-derived ex vivo-expanded cellular therapy product that has dem-onstrated faster engraftment and fewer infections compared with unmanipulated UCB in allogeneic hematopoietic cell transplantation. Although the early benefits of omidubicel have been established, long-term outcomes remain unknown. We report on a planned pooled analysis of 5 multicenter clinical trials including 105 patients with hematologic malignancies or sickle cell hemoglobinopathy who underwent omidubicel transplantation at 26 academic transplantation centers worldwide. With a median follow-up of 22 months (range, .3 to 122 months), the 3-year estimated overall survival and disease-free survival were 62.7% and 56.4%, respectively. With up to 10 years of follow-up, omidubicel showed durable trilineage hematopoiesis. Serial quantitative assessments of CD3(+), CD4(+), CD8(+), CD19(+), CD116(+)CD56(+), and CD123(+) immune subsets revealed median counts remaining within normal ranges through up to 8 years of follow-up. Secondary graft failure occurred in 5 patients (5%) in the first year, with no late cases reported. One case of donor-derived myeloid neoplasm was reported at 40 months post-transplantation. This was also observed in a control arm patient who received only unmanipulated UCB. Overall, omidubicel demonstrated stable trilineage hematopoiesis, immune competence, and graft durability in extended follow-up. (c) 2023 The American Society for Transplantation and Cellular Therapy.
- Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults(2020) CHIESA, Robert; WANG, Junfeng; BLOK, Henric-Jan; HAZELAAR, Sheree; NEVEN, Benedicte; MOSHOUS, Despina; SCHULZ, Ansgar; HOENIG, Manfred; HAUCK, Fabian; SERAIHY, Amal Al; GOZDZIK, Jolanta; LJUNGMAN, Per; LINDEMANS, Caroline A.; FERNANDES, Juliana F.; KALWAK, Krzysztof; STRAHM, Brigitte; SCHANZ, Urs; SEDLACEK, Petr; SYKORA, Karl-Walter; AKSOYLAR, Serap; LOCATELLI, Franco; STEPENSKY, Polina; WYNN, Robert; LURN, Su Han; ZECCA, Marco; PORTA, Fulvio; TASKINEN, Mervi; GIBSON, Brenda; MATTHES, Susanne; KARAKUKCU, Musa; HAURI-HOHL, Mathias; VEYS, Paul; GENNERY, Andrew R.; LUCCHINI, Giovanna; FELBER, Matthias; ALBERT, Michael H.; BALASHOV, Dmitry; LANKESTER, Arjan; GUNGOR, Tayfun; SLATTER, Mary A.Chronic granulomatous disease (CGD) is a primary immunodeficiency resulting in life-threatening infections and inflammatory complications. Allogeneic hematopoietic cell transplantation (allo-HCT) can cure the disease, but the indication to transplant remains controversial. We performed a retrospective multicenter study of 712 patients with CGD who underwent allo-HCT transplantation from March 1993 through December 2018. We studied 635 children (aged <18 years) and 77 adults. Median follow-up was 45 months. Median age at transplantation was 7 years (range, 0.1-48.6). Kaplan-Meier estimates of overall survival (OS) and event-free survival (EFS) at 3 years were 85.7% and 75.8%, respectively. In multivariate analysis, older age was associated with reduced survival and increased chronic graft-versus-host disease. Nevertheless, OS and EFS at 3 years for patients >= 18 years were 76% and 69%, respectively. Use of 1-antigen-mismatched donors was associated with reduced OS and EFS . No significant difference was found in OS, but a significantly reduced EFS was noted in the small group of patients who received a transplant from a donor with a >1 antigen mismatch. Choice of conditioning regimen did not influence OS or EFS. In summary, we report an excellent outcome after allo-HCT in CGD, with low incidence of graft failure and mortality in all ages. Older patients and recipients of 1-antigen-mismatched grafts had a less favorable outcome. Transplantation should be strongly considered at a younger age and particularly in the presence of a well-matched donor.
- Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease in a Single Institution in Brazil. Reproducing Good Results with a Reduced Toxicity Regimen(2017) FERNANDES, Juliana Folloni; MANTOVANI, Luiz Fernando Alves Lima; VENANCIO, Angela Mandelli; DORNA, Mayra; PASTORINO, Antonio Carlos; VASCONCELOS, Dewton; NETO, Antonio Condino; MOURA, Ana Carla Augusto; COLLASSANTI, Maria Dulce; ZANICHELLI, Maria Aparecida; CARNEIRO-SAMPAIO, Magda; ROCHA, Vanderson G.; ODONE FILHO, Vicente
conferenceObject RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME: SINGLE INSTITUTION RETROSPECTIVE STUDY(2022) MACHADO, Ana Rahal Guaragna; FLORES, Angelica Hidalgo; SILVA, Aline Rodrigues Da; ZAMPERLINI-NETTO, Gabriele; BECHARAMAFRA, Ana; BARBUTO, Tomas Marzagao; CRISTOFANI, Lilian; ODONE FILHO, Vicente; GARCIA, Julia Lopes; FERNANDES, Juliana Folloni- Hematopoietic cell transplantation for Diamond Blackfan anemia: A report from the Pediatric Group of the Brazilian Bone Marrow Transplantation Society(2020) DARRIGO JR., Luiz Guilherme; LOTH, Gisele; KUWAHARA, Cilmara; VIEIRA, Ana; COLTURATO, Vergilio; RODRIGUES, Ana Luiza; ARCURI, Leonardo; FERNANDES, Juliana; MACEDO, Antonio; TAVARES, Rita; GOMES, Alessandra; RIBEIRO, Lisandro; SEBER, Adriana; ZECCHIN, Victor; SOUZA, Mair de; CALIXTO, Rodolfo; PASQUINI, Ricardo; FLOWERS, Mary; ROCHA, Vanderson; BONFIM, CarmemObjectives The aim of this study was to analyze the outcomes of children with Diamond-Blackfan anemia (DBA) treated in Brazil with hematopoietic cell transplantation (HCT). Methods We performed a retrospective analysis of 44 pediatrics patients transplanted between 1990 and 2018. The median age of patients was 5 years, and 57% were male. Twenty-five received their first HCT from an HLA-matched sibling donor (MSD), 12 from a HLA matched unrelated bone marrow donor (MUD 10/10, n = 12) and 7 other HLA mismatched donors (MMD). Results After a median follow-up of 4 years, estimate 5-year overall survival (OS) for the entire cohort was 70%, 80% for MSD group, 73% for MUD, and 29% for MMD. Thirty-eight out of the 44 evaluable patients engrafted successfully. Primary and secondary graft failure was observed in five and three patients, respectively. Rates of grade II-IV and III-IV acute graft-versus-host disease (aGVHD) were 25% and 18%, respectively. Nine patients developed chronic GVHD (cGVHD). Conclusion Overall survival rates observed after HLA matched donors transplant for DBA were comparable to those reported from higher-income countries and international registries.
conferenceObject Allogeneic bone marrow transplantation for children and adolescents with severe aplastic anemia in Brazil: A multicenter study on behalf of the Brazil-Seattle Consortium Study Group(2018) DARRIGO JR., Luiz; COULTURATO, Vergilio; SOUZA, Mair; MATTOS, Ederson; LOTH, Gisele; CALIXTO, Rodolfo; SEBER, Adriana; ZECCHIN, Victor; DAUDT, Liane; PAZ, Alessandra; TAVARES, Rita Barbosa; ARCURI, Leonardo; MACEDO, Antonio; VIEIRA, Ana Karine; KUWAHARA, Cilmara; GOUVEIA, Roseane; RIBEIRO, Lisandro; FERNANDES, Juliana; FLOWERS, Mary; PASQUINI, Ricardo; BONFIM, CarmemconferenceObject Relapsed Acute Lymphoblastic Leukemia and Blinatumomab: Results From a Single Institution in Brazil Universidade de Sao Paulo(2020) ZAMPERLINI-NETTO, G.; FONSECA, M.; ALMEIDA, M.; ODONE-FILHO, V.; TEIXEIRA, R.; FERNANDES, J.; AZAMBUJA, A.; DUTRA, A.; BREVIGLIERI, C.; CRISTOFANI, L.